BMS-929075
BMS-929075 is a potent and orally active HCV NS5B replicase palm site allosteric inhibitor. BMS-929075 shows high oral bioavailability. BMS-929075 shows cytotoxicity.
For research use only. We do not sell to patients.
- CAS No.: 1217338-97-0
- Formula: C31H24F2N4O3
- Molecular Weight:538.54
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | CC50 |
>50 μM
Compound: 37; BMS-929075
|
Cytotoxicity against primary human hepatocytes
Cytotoxicity against primary human hepatocytes
|
[PMID: 28430437] |
| HepG2 | CC50 |
>12.5 μM
Compound: 37; BMS-929075
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 28430437] |
| Huh-7 | CC50 |
60 μM
Compound: 37; BMS-929075
|
Cytotoxicity against human HuH7 cells after 3 days by CellTiter-Blue assay
Cytotoxicity against human HuH7 cells after 3 days by CellTiter-Blue assay
|
[PMID: 28430437] |
In Vitro
BMS-929075 (0-60 µM) shows cytotoxicity with CC50 values of 60, >12.5, >50 µM for Huh-7, HepG2, primary human hepatocytes, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Pharmacokinetic Parameters of BMS-929075 in Male Sprague-Dawley rats[1].
| IV | PO | |||||||||
| species | Cl (mL/min/kg) | IV t1/2(hr) | Vss(L/kg) | Cmax(µM) | Tmax(hr) | AUC (µM h) | C6 liver (µM) | C24 liver (µM) | C24 liver/plasma (µM) | F% (mL/min/kg) |
| rat | 1.7 | 4.7 | 0.7 | 7.5 | 4 | 54.5 | 15.1 | 1.12 | 1.6 | 48 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1217338-97-0
-
Molecular Weight 538.54
-
Formula C31H24F2N4O3
-
SMILES
O=C(C1=CC(C2=C(F)C3=C(OC(C4=CC=C(F)C=C4)=C3C(NC)=O)C=C2)=C(C)C=C1)NC5(CC5)C6=NC=CC=N6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)